The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

October 14, 2026

Conditions
GoutUric Acid
Interventions
DRUG

Febuxostat

The minimal approved dose of febuxostat is 40 mg/day. We will use 0.5 tablet of febuxostat 40 mg or its placebo.

Trial Locations (1)

463-707

Seoul National University Bundang Hospital, Seongnam-si

All Listed Sponsors
collaborator

Gachon University Gil Medical Center

OTHER

collaborator

SMG-SNU Boramae Medical Center

OTHER

collaborator

Chungnam National University Hospital

OTHER

collaborator

Seoul National University Bundang Hospital

OTHER

collaborator

Eulji University Hospital

OTHER

collaborator

Ajou University Medical Center

UNKNOWN

lead

Seoul National University Hospital

OTHER

NCT06622603 - The Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More | Biotech Hunter | Biotech Hunter